Hikma Pharmaceuticals strongly objects to the use of its products in capital punishment

London, 15 May 2013 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) notes the press release issued today by the legal action charity Reprieve, regarding the potential use of its injectable phenobarbital for the purpose of capital punishment by the Arkansas Department of Corrections.

Press Release Corporate 15 May 2013

Phenobarbital is the world’s most widely used anti-convulsant. Hikma strongly objects to the use of any of its products in capital punishment. The Company is putting in place concrete steps to restrict the supply of its products for unintended uses. It has ceased the direct sale of injectable phenobarbital to US departments of corrections and will work directly with its distribution partners to add restrictions for unintended use to its distribution contracts.

Hikma aims to improve lives by providing patients with access to high-quality, affordable medicines. Its medicines are used thoUSnds of times a day to treat illness and save the lives of patients across its markets.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.